Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P150025/S020

PD-L1 IHC 28-8 pharmDx

Agilent Technologies, Inc. · Decision date Sep 11, 2026

MEDTECHLEDGER EXPLANATIONP150025/S020

What did the FDA decide?

The FDA recorded decision OK30 on 2026-09-11 for P150025/S020, a 30-Day Notice supplement to the PMA for PD-L1 IHC 28-8 pharmDx, submitted by Agilent Technologies, Inc. The listed specialty is Pathology. The recorded supplement reason is a process change affecting manufacturer, sterilizer, packager or supplier arrangements.

The recorded statement covers approval of manufacturing process and equipment changes for filling and capping. This is a supplement-level action tied to the existing PMA, not a new approval of the device as a whole. The source does not identify the specific filling or capping equipment, the manufacturing site, or any validation data, and it gives no clinical, analytical performance or labeling information. Whether the change affects device performance or current labeling cannot be determined from this record.

FDA approval order statement

approval of manufacturing process and equipment changes for filling and capping
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Pathology
Decision date
Sep 11, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150025/S020
Regulatory pathway
PMA supplement
Product code
Not reported
Decision code
OK30
Decision date
Sep 11, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

Product code
Not reported

For the original device and its historical approval scope, see PMA P150025. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P150025 · Original PMA

    PD-L1 IHC 28-8 pharmDx

  2. P150025/S020 received

    Application receipt date recorded by FDA.

  3. P150025/S020 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P150025. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150025

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA approvalOct 9, 2015FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records